Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

BACKGROUND: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. There is a lack of comp...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ommen-Nijhof, A., Konings, I. R., van Zeijl, C. J. J., Uyl-de Groot, C. A., van der Noort, V., Jager, A., Sonke, G. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247672/
https://www.ncbi.nlm.nih.gov/pubmed/30458732
http://dx.doi.org/10.1186/s12885-018-4978-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247672/
https://www.ncbi.nlm.nih.gov/pubmed/30458732
http://dx.doi.org/10.1186/s12885-018-4978-1

Ejemplares similares